| Biomarker ID | 1655 |
| PMID | 30958910 |
| Year | 2019 |
| Biomarker | miRâ€28; miRâ€100; miRâ€942; miRâ€28â€3p |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Low Grade Vs High Grade Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | There were 66 men, aged 46â€86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | miRâ€28: p=0.016; miRâ€100: p=0.025; miRâ€942: p=0.025; miRâ€28â€3p: p=0.038 |
| Method Used | NA |
| Clinical | No |
| Remarks | Low-Grade meant (Gleason score, 6 or 7 [3 + 4] and serum prostateâ€specific antigen [PSA], <20 ng/mL) and high-Grade meant (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |